$2.42
13.62% yesterday
Nasdaq, May 06, 10:15 pm CET
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Heron Therapeutics Inc Stock News

Neutral
Seeking Alpha
about 12 hours ago
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Conference Call Participants Yuxi Dong - Jefferies Serge Belanger - Needham & Company Carl Byrnes - Northland Capital Markets Operator ...
Neutral
PRNewsWire
about 16 hours ago
Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI ® and APONVIE ® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025 CARY, N.C. , May 6, 2025 /PRNewswire/ -- He...
Neutral
PRNewsWire
about 16 hours ago
— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve...
Neutral
PRNewsWire
8 days ago
CARY, N.C. , April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry.
Neutral
PRNewsWire
14 days ago
CARY, N.C. , April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights.
Neutral
Seeking Alpha
2 months ago
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Bill Forbes - Executive Vice President, Chief Development Officer Kevin Warner - Senior Vice President, Medical Affairs, Strategy...
Neutral
PRNewsWire
2 months ago
Achieved Q4 2024 GAAP Net Income of $3.6 million Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year Delivered full-year 2024 adjusted EBITDA of $8.6 million Generated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024 U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi US...
Neutral
PRNewsWire
3 months ago
CARY, N.C., Feb. 13, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 27, 2025, at 8:00 a.m.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today